Crescendo Bioscience is a molecular diagnostics company focused on rheumatology that develops quantitative, objective blood tests to guide treatment of autoimmune and inflammatory diseases. Its lead product, Vectra DA, integrates concentrations of 12 serum proteins into a single score to assess rheumatoid arthritis (RA) disease activity. All Vectra DA testing is performed at Crescendo’s CLIA-certified laboratory, with results returned 7–10 days and delivered by mail, fax, or a private web portal. The company works with academic collaborators to characterize protein, gene expression, and genetic biomarkers to provide molecular analysis of RA. Crescendo aims to expand commercialization and clinical development to increase availability of Vectra DA and build long-term relationships with clinicians to improve patient outcomes. The company emphasizes addressing an unmet need in RA, a disease affecting over 1.5 million people in the U.S. and more than 4 million worldwide. Crescendo Bioscience is a South San Francisco molecular diagnostics company developing quantitative biomarker tests for rheumatoid arthritis and other inflammatory diseases. Its lead product, Vectra DA, is a blood-based molecular diagnostic designed to determine disease activity in patients with rheumatoid arthritis. The company plans to use the new funding to accelerate commercialization of Vectra DA and to expand its pipeline of molecular diagnostic products for rheumatoid arthritis and other inflammatory diseases. Crescendo completed a $31M Series C equity financing led by aeris CAPITAL AG with participation from existing investors Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers and others, and entered a strategic agreement with Myriad Genetics for $25M. The Myriad investment is non-dilutive, structured as long-term debt and includes a three-year option to acquire Crescendo. Management includes CEO William A. Hagstrom and a leadership team spanning medical, scientific, commercial and finance functions.

Total raised

$84M

Funding rounds

3

Latest round

Series D

Latest activity

Jan 2013